A Retrospective Chart Review of Intramuscular Ziprasidone for Agitation in Children and Adolescents on Psychiatric Units: Prospective Studies Are Needed
Authors:
- 1 August 2007
- journal article
- review article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 17 (4) , 503-509
Abstract
Our primary objective was to evaluate the effectiveness and tolerability of intramuscular ziprasidone for impulsivity and agitation in psychiatrically hospitalized children and adolescents. Our secondary objective was to examine demographic and clinical factors associated with treatment response. We conducted a retrospective chart review of children and adolescents admitted to Cincinnati Children's Hospital Medical Center (CCHMC) psychiatric units between January 1, 2002, and July 11, 2005, who received intramuscular ziprasidone. Medical records were reviewed to determine demographic and clinical information as well as tolerability and effectiveness of ziprasidone. The Behavioral Activity Rating Scale (BARS) was used retrospectively to assess clinical response. Regression analyses were performed to evaluate the effect of demographic factors (age, gender, and ethnicity) and primary psychiatric diagnoses on treatment response. Electrocardiogram (ECG) data was inadequate. Fifty nine children and adolescents received a total of 77 injections of intramuscular ziprasidone for acute agitation. The mean +/- SD BARS score decreased from 6.5 +/- 0.7 to 3.1 +/- 1.3. The most common side effect was drowsiness or falling asleep (n = 46, 60%). Three (4%) could not be roused after the injection. Intramuscular ziprasidone may be helpful for agitation but often caused oversedation. Safety data, including ECGs, is needed in controlled prospective studies.Keywords
This publication has 11 references indexed in Scilit:
- Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidolPsychopharmacology, 2006
- Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2005
- Pharmacokinetics and Therapeutics of Acute Intramuscular ZiprasidoneClinical Pharmacokinetics, 2005
- Intramuscular Ziprasidone in Youth: A Retrospective Chart ReviewJournal of Child and Adolescent Psychopharmacology, 2004
- Intramuscular Ziprasidone for Acute Agitation in AdolescentsJournal of Child and Adolescent Psychopharmacology, 2004
- Validation of the behavioural activity rating scale (BARS)™: a novel measure of activity in agitated patientsJournal of Psychiatric Research, 2002
- Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialPsychopharmacology, 2001
- Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic PatientsThe Journal of Clinical Psychiatry, 2001
- Intramuscular Ziprasidone Compared With Intramuscular Haloperidol in the Treatment of Acute PsychosisThe Journal of Clinical Psychiatry, 2000
- Predictors of acute dystonia in first-episode psychotic patientsAmerican Journal of Psychiatry, 1994